Skip to main content

Table 1 Clinicopathologic characteristics of 151 patients

From: Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy

   Pt. number %
Sex M 3 2.0%
  F 148 98.0%
Age median 46 years range 28–70 years
  ≤50 111 73.5%
  > 50 40 26.5%
Surgery MRM 120 79.5%
  BCS 31 20.5%
Histology ductal 138 91.4%
  others 13 8.6%
Stage IIIA 79 52.3%
  IIIC 72 47.7%
Tumor size pT ≤ 2 cm 11 7.3%
  2 < pT ≤ 5 110 72.8%
  pT > 5 cm 30 19.9%
Involved LNs 4–9 79 52.3%
  ≥10 72 47.7%